key: cord-0946462-pz5uhitv
authors: Hubiche, T.; Le Duff, F.; Fontas, E.; Rapp, J.; Chiaverini, C.; Passeron, T.
title: Relapse of chilblain‐like lesions during the second wave of the COVID‐19 pandemic: a cohort follow‐up
date: 2021-07-05
journal: Br J Dermatol
DOI: 10.1111/bjd.20584
sha: 8041aaa7f13a52d9aa0ed473347ed94bb567858f
doc_id: 946462
cord_uid: pz5uhitv

Chilblain-like lesions have been reported during the COVID-19 pandemic. Studies based on serology and rt-PCR exploring the causal link between chilblains and COVID-19 infection reported conflicting results1-3 . However, a significant proportion of patients who developed chilblains reported they had contact with COVID-19 suspected cases4 . Europe faced a second pandemic wave since October 2020.

DOI: 10.1111/bjd.20584 DEAR EDITOR, Chilblain-like lesions have been reported during the COVID-19 pandemic. Studies based on serology and RT-PCR (reverse-transcriptase polymerase chain reaction) exploring the causal link between chilblains and COVID-19 infection have reported conflicting results. [1] [2] [3] However, a significant proportion of patients who developed chilblains reported they had contact with suspected cases of COVID-19. 4 Europe has faced a second wave of the pandemic since October 2020. As we had observed in our area, a new outbreak of chilblains was also reported in Italy concomitantly with the second wave. 5 Recently, the first relapses in patients who experienced chilblains during the first wave were reported. 5 The aim of this study was to explore, in our cohort of chilblain-like lesions, 4 the occurrence of relapses and exposure to COVID-19 in households during the second wave.

The 40 patients in the cohort (NCT04344119) were systematically contacted by phone between 5 and 10 February 2021. When needed, a teleconsultation was also performed. Thirtytwo of the 40 patients responded to the survey (response rate of 80%). Clinical and virological information relative to the second-wave period since October 2020 were registered on a standardized form. Twenty patients (63%) among the 32 who responded to the survey reported relapses (Table 1 ). Patients experiencing relapses had similar clinical presentation to the first episode observed during the first wave. No severe complications were reported. Thirteen patients with relapse had undergone COVID-19 RT-PCR since October 2020, along with four in the group without relapse. These tests had been done for several reasons (travel, tests required by their jobs, positive contacts in household or at work). The median delay between the onset of chilblains and the RT-PCR test was 0 days (range À34 to +105, interquartile range 46). Only one patient had a positive RT-PCR. He was in the group who reported chilblainlike lesions. However, the test was performed 63 days before the chilblains occurred. He was asymptomatic and was tested because symptomatic COVID-19 infection was diagnosed in his father and mother.

Among the 19 households with the 20 cases of relapse, a possible COVID-19 infection was reported in six (32%). This was confirmed by PCR in four households (total of five members) of patients with relapsed chilblains. In households where patients had chilblains in the past but did not have relapses, no household members or family members had suspected COVID-19. COVID-19 household infections were reported within 2 months of the relapse of the related chilblains, with 75% occurring within 2 weeks (median 3Á5 days, range À9 to +63, interquartile range 0). Simultaneous occurrence of chilblains was observed in one other member of four households of patients who experienced relapse, suggesting that they were exposed to the same trigger event.

We observed a relatively high frequency of relapses in our chilblain-like cohort. These relapses were contemporary with the second wave of the COVID-19 pandemic in our region. Recent data suggested that recurrent pernio could be linked to exposure to cold temperature. 6 In our area, the mean minimum and maximum temperatures ranged from 12Á7°C and 19Á6°C in October 2020 to 5Á3°C and 14Á6°C in January 2021. We cannot exclude that those relapses were caused by the return of the cold season triggering relapse on a previously altered microcirculation. Recurrent pernio occurs after cold exposure in genetic interferonopathies, supporting a seasonal explanation for the relapses. However, one-third of the patients who had relapses were exposed to possible or proven cases of COVID-19 within the household, and infections in the household were observed in 75% of cases within 2 weeks of the relapse of chilblain-like lesions. Conversely, COVID-19 infection was not reported in any patients or their households in the no-relapse group. Only one patient with relapse had a positive PCR test. Despite proven circulation of the virus in the household, virological confirmation of infection is lacking in most patients.

Chilblain-like lesions associated with the COVID-19 pandemic have been suggested as interferon type I-related skin manifestations due to an efficient antiviral response in those patients. 4, 7 Efficient antiviral immune response has been proposed to explain the absence of virological confirmation in children exposed to COVID-19 within households. 8 This probably explains the difficulties in proving a causal link based on a positive RT-PCR and/ or serology between chilblain-like lesions and COVID-19.

Taken together, our results suggest an eventual high risk of relapses in patients who have had a previous episode of chilblains in the context of COVID-19 infection. Our data suggest that re-exposure to SARS-CoV-2 infection might trigger a relapse in chilblain-like lesions, although we cannot exclude that an initial insult from SARS-CoV-2, followed by subsequent cold exposure, could trigger these relapses in some cases.

T. Hubiche iD , 1 F. Le Duff iD , 1 E. Fontas iD , 2 J. Rapp, 1 C. Chiaverini iD 1 and T. Passeron iD 1, 3 

Evaluation of chilblains as a manifestation of the COVID-19 pandemic

A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection

Negative SARS-CoV-2 PCR in patients with chilblain-like lesions

Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic

Relapse of chilblain-like lesions during the second wave of COVID-19

Cold and COVID: recurrent pernio during the COVID-19 pandemic

COVID toes'): histologic, immunofluorescence, and immunohistochemical study of 17 cases

Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19